Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Efficacy and Safety Study of Oral Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)

NCT03312634 is registered in ClinicalTrials.gov with Clementia Pharmaceuticals Inc. as lead sponsor.

NCT NCT03312634
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03312634 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Efficacy and Safety Study of Oral Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)
Lead sponsor
Clementia Pharmaceuticals Inc.
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2017
Completion date
September 7, 2022
Enrollment
107 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

fibrodysplasia ossificans progressiva